WallStSmart

Medtronic PLC (MDT)vsNeuroone Medical Technologies Corp (NMTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 300990% more annual revenue ($37.54B vs $12.47M). MDT leads profitability with a 13.9% profit margin vs -59.7%. MDT earns a higher WallStSmart Score of 68/100 (B-).

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99

NMTC

Avoid

28

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: -8.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Intrinsic value data unavailable for NMTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

NMTC2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Areas to Watch

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

NMTC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.75M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-123.6%2/10

ROE of -123.6% — below average capital efficiency

Free Cash FlowQuality
$-1.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bull Case : NMTC

The strongest argument for NMTC centers on Debt/Equity, Revenue Growth. Revenue growth of 16.3% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Bear Case : NMTC

The primary concerns for NMTC are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MDT profiles as a value stock while NMTC is a growth play — different risk/reward profiles.

NMTC carries more volatility with a beta of 0.64 — expect wider price swings.

NMTC is growing revenue faster at 16.3% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 28/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Neuroone Medical Technologies Corp

HEALTHCARE · MEDICAL DEVICES · USA

NeuroOne Medical Technologies Corporation is a medical technology company. The company is headquartered in Eden Prairie, Minnesota.

Visit Website →

Want to dig deeper into these stocks?